SCHEMBL13675634

SCHEMBL13675634

CC(C)(C)c1ccc(/C=C/C(=O)Nc2ccccc2O)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 5/20 0.72
MMP2 P08253 5/20 0.72
MMP9 P14780 5/20 0.72
TRPV1 Q8NER1 6/20 0.70
TNIK Q9UKE5 1/20 0.70
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
LMNA P02545 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
KDM1A O60341 1/20 0.60
MAPT P10636 2/20 0.58
KDM4E B2RXH2 1/20 0.58
POLB P06746 1/20 0.58
HPGD P15428 1/20 0.58
MAPK1 P28482 1/20 0.58
HDAC1 Q13547 1/20 0.57
MAOB P27338 1/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
TP53 P04637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13675779 0.86 MMP1 (0.74) MMP1MMP2MMP9TRPV1TNIK
SCHEMBL13675644 0.85 TRPV1 (0.69) MMP1MMP2MMP9TRPV1TNIK
N-(2-Hydroxyphenyl)Cinnamamide SCHEMBL2305883 0.84 MMP1 (1.00) MMP1MMP2MMP9NPC1RAB9A
N-(2-Hydroxyphenyl)Cinnamamide SCHEMBL9989385 0.84 MMP1 (1.00) MMP1MMP2MMP9NPC1RAB9A
N-(2-Hydroxyphenyl)Cinnamamide SCHEMBL2305881 0.84 MMP1 (1.00) MMP1MMP2MMP9NPC1RAB9A
N-(2-Hydroxyphenyl)Cinnamamide SCHEMBL30311315 0.84 MMP1 (1.00) MMP1MMP2MMP9NPC1RAB9A
SCHEMBL13675885 0.83 TRPV1 (1.00) MMP1MMP2MMP9TRPV1TNIK
SCHEMBL13675771 0.83 TRPV1 (0.75) TRPV1TNIKNPC1RAB9ALMNA
SCHEMBL13675867 0.83 TNIK (1.00) TRPV1TNIKNPC1RAB9ALMNA
SCHEMBL13675649 0.83 TRPV1 (0.66) MMP1MMP2MMP9TRPV1TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
EP-1780196-A2 Pyridine derivatives for use as vanilloid receptor ligands Amgen, Inc (US) 2007-05-02 EP disclosed
EP-1764358-A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain Amgen, Inc (US) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 MMP1 1052/4885MMP2 1236/4885MMP9 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.